苯环喹溴铵治疗变应性鼻炎的真实世界数据回顾性研究  

A Retrospective Study with Real-world Data on Bencycloquidium Bromide in the Treatment of Allergic Rhinitis

作　　者：田昊[1] 夏交[1] 吴松林 冯启苗 杨晓宇 纪周群[5] 王殿一[6] 李枫 赵红 董瑞[9] 杨艳莉 TIAN Hao;XIA Jiao;WU Song-lin;FENG Qi-miao;YANG Xiao-yu;JI Zhou-qun;WANG Dian-yi;LI Feng;ZHAO Hong;DONG Rui;YANG Yan-li(Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China;Zhangjiajie People's Hospital,Zhangjiajie 427000,China;Tongji Hospital,Tongji Medical College of HUST,Wuhan 430030,China;Xi'an Gaoxin Hospital,Xi'an 710075,China;Affiliated Hospital of Jiangsu University,Zhenjiang 212001,China;First Affiliated Hospital,Heilongjiang University of Chinese Medicine,Harbin 150040,China;Chongqing University Three Gorges Hospital,Chongqing 404000,China;First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300073,China;Second Hospital of Shanxi Medical University,Taiyuan 030032,China;The Affiliated Hospital of Yunnan University,Kunming 650032,China)

机构地区：[1]首都医科大学附属北京友谊医院,北京100050 [2]张家界市人民医院,张家界427000 [3]华中科技大学同济医学院附属同济医院,武汉430030 [4]西安高新医院,西安710075 [5]江苏大学附属医院,镇江212001 [6]黑龙江中医药大学附属第一医院,哈尔滨150040 [7]重庆大学附属三峡医院,重庆404000 [8]天津中医药大学第一附属医院,天津300073 [9]山西医科大学第二医院,太原030032 [10]云南大学附属医院,昆明650032

出　　处：《中国合理用药探索》2025年第3期106-111,共6页Chinese Journal of Rational Drug Use

摘　　要：目的:本研究旨在探讨苯环喹溴铵鼻喷剂治疗变应性鼻炎(AR)的疗效,并进一步探究治疗效果的影响因素。方法:回顾性选取2022年1月~2023年1月就诊于全国10家医院的患者病历资料。患者接受苯环喹溴铵治疗或苯环喹溴铵联合鼻喷激素/抗组胺药物治疗,记录治疗前后鼻部症状总评分(TNSS)、非鼻部伴随症状评分(TNNSS)。根据显效、有效、无效对疗效进行评价,并分析AR类型、合并症、病程对于疗效的影响。结果:本研究共纳入669例AR患者。所有患者治疗前后TNSS差值为-5.38(P<0.001);临床治疗总有效率97.31%,显效率87.89%。在>6岁、4种AR类型、病程<1年或≥1年的各亚组中,临床治疗总有效率均>88.99%。流涕、鼻塞、鼻痒、喷嚏4个单项鼻部症状在治疗后评分均下降,其中流涕下降最多。中重度间歇性AR患者治疗后联合治疗组TNSS平均差值比单独治疗组更大(-5.79 vs.-5.70,P<0.05);中重度持续性AR患者治疗后联合治疗组TNSS和TNNSS平均差值比单独治疗组更大,TNSS平均差值为(-6.32 vs.-6.30,P<0.05);TNNSS平均差值为(-1.61vs.-1.27,P<0.05)。结论:苯环喹溴铵鼻喷剂可降低AR患者的TNSS以及TNNSS,对不同年龄及不同类型患者均有较好疗效,对于中重度AR患者,推荐苯环喹溴铵鼻喷剂联合鼻喷激素/抗组胺药物用药。Objective:To investigate the efficacy of bencycloquidium bromide nasal spray in the treatment of allergic rhinitis(AR),and further explore the factors influencing its therapeutic effects.Methods:A retrospective selection of medical records from patients treated in 10 hospitals nationwide between January 2022 and January 2023 was conducted.The patients were treated with bencycloquidium bromide alone or bencycloquidium bromide combined with corticosteroid nasal spray/antihistamine.Total nasal symptom score(TNSS)and total non-nasal symptom score(TNNSS)were recorded before and after treatment.The efficacy was evaluated based on the criteria of marked response,response,and no response.Additionally,the effects of AR type,comorbidities,and disease duration on the efficacy were analyzed.Results:A total of 669 patients with AR were included in this study.The difference of TNSS in all patients before and after treatment was-5.38(P<0.001).The total response rate was 97.31%and the marked response rate was 87.89%.In subgroups with an age greater than 6 years old,four AR types,and disease duration(<1 year or≥1 year),the total response rate based on the reduction in TNSS scores was greater than 88.99%.The scores for all four individual nasal symptoms(rhinorrhoea,nasal obstruction,nasal itching,and sneezing)were decreased after treatment,with the most notable reduction observed in rhinorrhoea.In moderate-to-severe intermittent patients,the combination therapy group demonstrated a greater reduction in TNSS compared to the monotherapy group(-5.79 vs.-5.70,P<0.05).For moderate-to-severe persistent patients,the combination therapy group showed larger decreases in both TNSS and TNNSS compared to the monotherapy group,with a TNSS difference of(-6.32 vs.-6.30,P<0.05)and a TNNSS difference of(-1.61 vs.-1.27,P<0.05).Conclusion:Bencycloquidium bromide nasal spray can reduce the TNSS and TNNSS scores in patients with AR,and shows good efficacy in patients of different ages and different AR types.For patients with moderate to severe AR,be

关 键 词：苯环喹溴铵 变应性鼻炎 鼻部症状 鼻部症状总评分 非鼻部伴随症状评分 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]